Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00972439 · ClinicalTrials.gov registry record · NA
Oral Contraceptive (OC) Progestin Dose and Breast Proliferation
A NA study of Oral Contraceptive, sponsored by University of Southern California.
- Completed
- Registry status
- NA
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT00972439: Completed NA study of Oral Contraceptive, sponsored by University of Southern California.
NCT00972439 is a NA study of Oral Contraceptive that has completed, run by University of Southern California. The registered enrollment target is 33 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00972439, a NA study of Oral Contraceptive, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to gain a better understanding of the changes that may occur in the breast when a woman uses an oral contraceptive (birth control pill). Some research indicates that women who use birth control pills with lower amounts of progestin (a hormone in the birth control pill) may have lower breast cell growth than women who use birth control pills with a higher amount of progestin; this research will examine that in detail.
Primary Outcome
Percent of cells expressing staining for Ki67 will be examined in breast epithelial cells
Conditions Studied
Interventions
- DRUG Oral Contraceptive: Ortho-Novum® 1/35
- DRUG Oral Contraceptive: Ovcon Fe®
Study Locations (1)
California
- Los Angeles County Hospital - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2007-08 |
| Est. Completion | 2008-11 |
| Phase | NA |
What the finished NCT00972439 record still lists
NCT00972439 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Oral Contraceptive appearing as the primary indexed condition, and to 2 interventions - of which Oral Contraceptive: Ortho-Novum® 1/35 is the first listed.
NCT00972439 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00972439 about?
NCT00972439 is a clinical study titled "Oral Contraceptive (OC) Progestin Dose and Breast Proliferation". The purpose of this research study is to gain a better understanding of the changes that may occur in the breast when a woman uses an oral contraceptive (birth control pill). Some research indicates that women who use birth control pills with lower amounts of progestin (a hormone in the birth contro...
What is the current status of trial NCT00972439?
This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2007-08. Estimated completion is 2008-11.
What conditions does trial NCT00972439 study?
This clinical trial studies the following conditions: Oral Contraceptive.
What interventions are being tested in trial NCT00972439?
The interventions under investigation include: Oral Contraceptive: Ortho-Novum® 1/35 (DRUG), Oral Contraceptive: Ovcon Fe® (DRUG).
Who is sponsoring clinical trial NCT00972439?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00972439 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00972439's enrollment target sits among peer trials
33 1574th of 2000 higher than 423 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia